Thyroid Cancer: A Clinical Overview and A Useful Laboratory Manual

Indexed in: Book Citation Index, Science Edition, EBSCO.

Thyroid nodules have a high prevalence in populations where iodine deficiency rates are high and in people older than 50 years. Considering that only 5-10% of thyroid nodules are of malignant nature, ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Tyrosine Kinase Inhibitor and Target Therapy

Pp. 85-95 (11)

Brilli Lucia

Abstract

“Tyrosine kinase inhibitors” (TKI) are small molecules responsible for selectively inhibiting cellular pathways involved in cell proliferation or migration. These molecules have been developed as alternative therapy for refractory or minimal responsive cancers to standard treatments. In this chapter, TKI currently used for anaplastic thyroid cancer, medullary thyroid cancer and/or refractory differentiated thyroid cancer will be described.

Keywords:

Tyrosine kinase, Tyrosine Kinase Inhibitors (TKI), growth factor receptors.

Affiliation:

Section of Endocrinology & Metabolism, Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Siena, Italy.